According to the National Health and Medical Research Council – NHMRC clinical trials across Australia are in the following categories:
– treatment trials to test new treatments, new medicines or combinations of medicines; or other new therapies such as surgery, the use of new medical devices or new approaches to surgery
– diagnostic or screening trials to evaluate tests or procedures to diagnose and detect diseases or conditions
– prevention trials to test new ways to prevent disease including medicines, vaccines, vitamins, or changes to diet, lifestyle or behaviour
Clinical trials in Australia need to be efficiently administrated and resourced with qualified healthcare professionals as well as suitable patients.
Shanny Dyer, CEO ARCS Australia talks about a recent summit where the CRO (Contract Research Organization) community was asked on the current state of clinical trials in Australia. Commentary from:
– Tanya Symons, Director at T Symons Associates
– Daniela Caiazza, Director Clinical Operations ANZ, Novotech CRO
– Adam Stoneley, Research Operations Manager, Icon Cancer Centre
– Gabrielle McKee, Chief Operating Officer, CNS Clinical Network
– Joe Taouk, Senior Director Research and Development, IQVIA
#AustralianHealthJournal #ClinicalTrials
-
Pathology technology at a crossroads
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
– Pathology Technology Australia’s key priorities in the coming years
– Current local capability in pathology technology compared to other countries
– How the health system supports change and adoption of pathology technology
– How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
– Observations in the Strengthening Medicare Taskforce ReportIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Emerging researcher appointed to James Packer Chair in Mood Disorders at UNSW
The UNSW Discipline of Psychiatry and Mental Health is widely renowned as the pre-eminent psychiatry research department in the country and one of the leading university psychiatry research groups internationally. In 2023 it celebrated 60 Years of Psychiatry & Mental Health at UNSW Sydney.
Australian Health Journal spoke with Professor Kimberlie Dean, Head of the Discipline of Psychiatry and Mental Health at UNSW Sydney, about the recent appointment of mental health disorders expert and clinician researcher Dr Aswin Ratheesh to lead the James Packer Chair in Mood Disorders at UNSW Sydney. -
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
